Examkin

Question

Difficulty: HardPharmacologic Interventions

A 54-year-old man presents to the clinic to discuss his medication regimen. He was diagnosed with active pulmonary tuberculosis earlier today and is scheduled to begin a standard empiric regimen of isoniazid, rifampin, pyrazinamide, and ethambutol. His past medical history is significant for a mechanical mitral valve replacement performed four years ago, for which he takes warfarin. His daily medications also include low-dose aspirin and metoprolol. His vital signs are within normal limits. Physical examination reveals a crisp mechanical click on cardiac auscultation and bronchial breath sounds in the right upper lung field. His international normalized ratio (INR) has been consistently stable at 3.0 for the past year, and today's INR is 2.9. Which of the following is the most appropriate next step in management regarding this patient's pharmacotherapy?

  1. Anticipate the need to increase the warfarin dosage and monitor the international normalized ratio frequentlyAnswer
  2. B
    Anticipate the need to decrease the warfarin dosage to mitigate the risk of severe bleeding
  3. C
    Transition from warfarin to a direct oral anticoagulant to avoid metabolic interactions
  4. D
    Withhold rifampin from the antitubercular regimen to prevent uncontrollable fluctuations in coagulation
  5. E
    Maintain the current warfarin dosage and monitor the activated partial thromboplastin time (aPTT)

Answer

Anticipate the need to increase the warfarin dosage and monitor the international normalized ratio frequently
The correct response anticipates the pharmacokinetic effects of rifampin on warfarin metabolism. Rifampin is a potent inducer of hepatic cytochrome P450 enzymes, primarily CYP2C9 and CYP3A4, which are responsible for metabolizing warfarin. Induction of these enzymes drastically accelerates the clearance of warfarin from the bloodstream. In a patient relying on warfarin to prevent thrombosis of a mechanical mitral valve, this accelerated clearance will rapidly lead to a subtherapeutic international normalized ratio (INR), exposing the patient to a critically high risk of valve thrombosis and systemic thromboembolism. Therefore, the most appropriate clinical intervention is to proactively monitor the INR on a frequent basis and anticipate the need to significantly increase the warfarin dosage to maintain the therapeutic target of 2.5 to 3.5.

Step-by-Step Solution

1
Identify the critical drug-drug interaction introduced by the new medication regimen.
The new tuberculosis regimen includes rifampin, which interacts significantly with the patient's chronic warfarin therapy.
Recognizing polypharmacy interactions is essential to prevent iatrogenic harm, particularly with narrow therapeutic index drugs like warfarin.
2
Determine the pharmacokinetic mechanism of the interaction.
Rifampin is a potent inducer of hepatic cytochrome P450 enzymes, specifically CYP2C9 and CYP3A4, which are responsible for the metabolism of warfarin.
Understanding whether an agent is an inducer or an inhibitor determines the direction of the dose adjustment required.
3
Predict the physiological outcome of the enzyme induction on the patient's coagulation status.
Increased CYP450 activity accelerates the clearance of warfarin, leading to a subtherapeutic international normalized ratio (INR) and a higher risk of mechanical valve thrombosis.
Clinical decision-making must preemptively address anticipated changes in drug efficacy before adverse events occur.
4
Select the appropriate pharmacologic intervention based on the predicted outcome and patient history.
The physician must anticipate the need to increase the warfarin dosage and monitor the INR closely, as alternative anticoagulants like DOACs are contraindicated for mechanical valves.
Standard of care requires vigilant monitoring and proactive dose titration when a known potent CYP inducer is initiated in a warfarin-dependent patient.

Key Concept

Pharmacokinetic drug interactions involving potent cytochrome P450 enzyme inducers (e.g., rifampin) and narrow therapeutic index substrates (e.g., warfarin) require proactive dose escalation and frequent monitoring to prevent therapeutic failure.
Estimated Time:1m 30s
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic